Adamis Pharmaceuticals Corp :A loss of 6 cents per share anticipated for first quarter

DMK Pharmaceuticals

10/09/2021 21:20

10 September 202108:20 p.m. All figures in US dollars. 
Adamis Pharmaceuticals Corp is expected to show an increase in
its first quarter earnings to -6 cents​ per share according to
the mean Refinitiv estimate from two analysts. Wall Street
expects results to range from a loss of -7 cents to ​a loss of
-5 cents per share.  
 
RECOMMENDATIONS 
* The single recommendation for the company is "Hold".  
* The average consensus recommendation for the pharmaceuticals
peer group is also "Hold". 
 
FORECAST CHANGES
* Two analysts are currently providing Refinitiv with
estimates. 
* In the last week there have been no earnings estimate
revisions by analysts covering the company. There were no
changes to the number of estimates.
* In the last four weeks the earnings per share estimate   is
unchanged  from -6 cents.  Estimates ranged from a high of -5
cents to a low of -7 cents.  There has been no changes to the
number of estimates.
* The StarMine predicted earnings surprise is currently
unavailable. Predicted revenue surprise is not available.
 
YEAR OVER YEAR
* The company is expected to report a fall in revenue to $3.47
million from $4.66 million in the same quarter last year.
* The current quarter consensus estimate of  -6 cents per
share   implies a gain of 60.00 percent from the same quarter
last year when the company reported -15 cents per share.
* Previous quarterly performance (using preferred earnings
measure)
 QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2021      0.26           0.29           Beat
 Mar. 31 2021      0.27           0.29           Beat
 Dec. 31  2020     0.31           0.35           Beat
 Sep. 30 2020      0.32           0.41           Beat
 
This summary was machine generated from Refinitiv data September
10 at 08:20 p.m